This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
Yesterday’s UK 100 Leaders | Price (p) | % Chg |
Barratt Developments PLC | 553.0 | 3.2% |
Burberry Group PLP | 707.8 | 3.1% |
Glencore PLC | 416.3 | 3.1% |
Fresnillo PLC | 547.0 | 2.8% |
Endeavour Mining PLC | 1,628.0 | 2.4% |
Yesterday’s UK 100 Laggards | Price (p) | % Chg |
Hikma Pharmaceuticals PLC | 2042.0 | -1.4% |
Spirax Group PLC | 7495.0 | -1.0% |
BAE Systems PLC | 1339.5 | -0.8% |
Admiral Group PLC | 2939.0 | -0.7% |
Rentokil Initial PLC | 483.8 | -0.6% |
Major World Indices | Price | % Chg | 1 Year |
UK 100 INDEX | 8,357 | 0.6% | 15.1% |
DOW JONES INDUS. AVG | 40,839 | 0.4% | 18.0% |
DAX INDEX | 18,422 | 0.5% | 18.3% |
NIKKEI 225 | 37,389 | -1.8% | 18.9% |
S&P/ASX 200 INDEX | 7,980 | 0.1% | 11.6% |
Commodities | Units | Price | % Chg |
WTI Crude Oil (Nymex) | USD/bbl. | 76.07 | -0.76% |
Brent Crude (ICE) | USD/bbl. | 79.03 | -0.82% |
Gold Spot | USD/t oz. | 2,503 | -0.2% |
Copper (Comex) | USd/lb. | 423 | 1.1% |
The UK 100 called to open -30 points at 8,327. The UK 100 looks set to open lower this morning, despite positive sessions from global markets both overnight and this morning, giving up some of the gains made later in the session yesterday.
Stocks advanced on Monday, on Wall Street after a sluggish start to the session building on the market’s comeback as investors started looking ahead to the closely watched Federal Reserve symposium later this week. The Dow Jones added 236.77 points, or 0.58%, to finish at 40,896.53. The S&P rose 0.97% to close at 5,608.25, while the Nasdaq jumped 1.39% and ended at 17,876.77. The S&P 500 and Nasdaq notched their eighth straight winning day, a first for both indexes in 2024.
In Tokyo, the Nikkei 225 stock index was up 2.1% to 38,156.41, recovering losses after a 1.8% drop the previous day. The yen briefly approached 145 against the U.S. dollar yesterday but then pulled back and traded at 146.94 this morning. China held its benchmark lending rates unchanged on Tuesday, with the one-year loan prime rate at 3.35% and the five-year LPR at 3.85%.
Antofagasta posted a 5% increase in their HY profit as higher copper prices more than offset lower sales. Their EBITDA for H1 rose to $1.39bn, up from $1.33bn last year, above analyst estimates. They reduced their interim dividend to 7.9 cents down from 11.7 cents.
AstraZeneca says Fasenra approved in China for severe eosinophilic asthma.
GSK says the US FDA have granted BTD for lung cancer treatment.
John Wood Group have reconfirmed their outlook, both for 2024 and 2025, including generating free cash flow in 2025.
Weir Group wins a £53m solutions contract for Barrick’s 50% owned Reko Diq project.
No new broker comments
UK
Antofagasta
Wood Group (John)
Oxford Instruments*
US
Medtronic
Xpeng
UK
US
Snowflake
Synopsys
Zoom Video Communications
PBoC Interest Rate Decision
German Producer Price Index
EU Core Harmonized Index of Consumer Prices
Fed’s Bostic speech
Fed’s Barr speech
Japanese Exports
Japanese Imports
Japanese Merchandise Trade Balance Total
UK 100 companies going ex-dividend on 22nd August 2024:
Legal & General Group
Schroders
Land Securities Group
Mondi
Imperial Brands
ConvaTec Group
UK 250 companies going ex-dividend on 22nd August 2024:
Investec
International Distribution Services
XPS Pensions Group
Personal Assets Trust
Hammerson
Babcock International Group
St. James’s Place
Shaftesbury Capital
Tritax Big Box REIT
Ibstock
Just Group
Witan Investment Trust
Temple Bar Investment Trust
OSB Group
For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.